Strategic partnerships Phantom Neuro has active collaboration history with major players and advocacy groups, including Blackrock Neurotech and Time BioVentures, as well as the Amputee Coalition. This presents opportunities to engage joint development programs, funding leads, or channel partnerships to expand market access.

Clinical trial access A published 2025 registry initiative connects upper-limb amputees with neurointerface trials, signaling a path to faster patient recruitment and broader trial enrollment. Sales outreach can target clinics, research centers, and hospitals seeking trial sites or patient sourcing.

Prosthetic integration Phantom X aims to enable intuitive control of prosthetic limbs via a minimally invasive neural interface. This creates conversations with prosthetics manufacturers, rehabilitation centers, and durable medical equipment distributors about co-development, integration, and product bundling.

Investment-backed validation With significant funding from reputable firms and a multi-million dollar funding round, Phantom Neuro demonstrates financial viability and growth trajectory. This can accelerate conversations with health tech investors, strategic buyers, and institutions evaluating scalable partnerships.

Public speaking momentum Leadership visibility at events like BioFuture 2025 indicates early adopter credibility and thought leadership. Use speaking engagements and press activity to open doors with enterprise customers, research hospitals, and government or defense health programs seeking innovative neural-interface solutions.